GUTS stock forecast, quote, news & analysis
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D)... Show more
GUTS Stock Fractyl Health (GUTS, $2.09) soared +51.45% in three months, becoming one of the top quarterly gainers among penny stocks
Fractyl Health, Inc. (NASDAQ: GUTS), a clinical-stage biotechnology company pioneering therapies for metabolic diseases like type 2 diabetes and obesity, is riding a notable uptrend, highlighted by its impressive quarterly performance among penny stocks. A.I.dvisor analyzed 759 other stocks in the Biotechnology Industry over the last three months, and discovered that 350 of them (46.07%) exhibited an Uptrend while 409 of them (53.93%) exhibited a Downtrend. Despite this mixed industry landscape, GUTS has defied the odds, soaring 51.45% in three months to $2.09, positioning it as a standout gainer and reflecting growing investor interest in its innovative pipeline. The company's advancements in endoscopic procedures and gene therapy approaches continue to fuel optimism, setting the stage for potential continued uptrend momentum in 2026 as metabolic health solutions gain traction globally.
Key Takeaways
- GUTS stock soared 51.45% over three months to $2.09, emerging as a top quarterly gainer among penny stocks.
- A.I.dvisor analysis reveals a split biotechnology sector, with 46.07% in uptrends and 53.93% in downtrends.
- Despite industry challenges, GUTS's performance highlights its resilience and investor appeal.
- Pipeline progress in Revita and new therapies underscores growth potential.
- Strategic expansions support sustained uptrend in metabolic disease treatments.
Fractyl Health focuses on developing minimally invasive therapies to address the root causes of metabolic diseases, particularly through altering gut physiology to improve insulin sensitivity and weight management. Its core offerings include the Revita system, an outpatient endoscopic procedure for duodenal mucosal resurfacing aimed at treating type 2 diabetes and obesity by rejuvenating the intestinal lining. The company emphasizes clinical-stage innovations that offer alternatives to traditional pharmaceuticals, serving patients seeking long-term metabolic improvements without lifelong medication dependence. With operations centered on research and development, Fractyl Health collaborates with healthcare providers and regulatory bodies to advance therapies that could transform chronic disease management.
In 2025, Fractyl Health advanced its pipeline with key developments and new initiatives. The company reported positive Phase 2 data for Revita in type 2 diabetes patients, showing sustained weight loss and glycemic control, paving the way for Phase 3 trials. A new gene therapy candidate was introduced for obesity, targeting gut hormones to enhance satiety and metabolism. Fractyl also launched a digital health service platform integrating Revita with app-based monitoring for post-procedure patient support, offering personalized nutrition guidance and remote consultations. Additionally, partnerships with endocrinology clinics expanded access to trial enrollments, while a biosimilar version of Revita for broader markets was submitted for regulatory review.
Complementing GUTS's uptrend analysis are advanced tools like Tickeron's AI trading bots, which provide sophisticated insights for investors. Tickeron's platform features AI-powered trading robots, virtual agents for stocks and ETFs, and single-ticker AI Trading Agents that are fully hedged with inverse ETFs for risk management. These bots use machine learning to deliver real-time signals, smart money management, and stock forecasts, with some achieving returns up to 158% in sectors like aerospace, mining, and ETFs. Tools such as A.I.dvisor, which analyzed GUTS's gain, scan historical patterns to predict outcomes, offering backtested algorithms for strategies like day trading on 60-minute intervals. With no prior trading experience required, these bots alert users to buys, sells, potential profits, and stop losses, making them valuable for spotting opportunities in stocks like GUTS during uptrends.
GUTS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 05, 2026
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 15 cases where GUTS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 17, 2026. You may want to consider a long position or call options on GUTS as a result. In of 36 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for GUTS just turned positive on June 17, 2026. Looking at past instances where GUTS's MACD turned positive, the stock continued to rise in of 18 cases over the following month. The odds of a continued upward trend are .
GUTS moved above its 50-day moving average on June 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in of 116 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for GUTS entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GUTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.274) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). GUTS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology